These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7226711)

  • 21. Encephalopathy from abuse of bismuth subsalicylate (Pepto-Bismol).
    Jungreis AC; Schaumburg HH
    Neurology; 1993 Jun; 43(6):1265. PubMed ID: 8192812
    [No Abstract]   [Full Text] [Related]  

  • 22. Structure of the active pharmaceutical ingredient bismuth subsalicylate.
    Svensson Grape E; Rooth V; Nero M; Willhammar T; Inge AK
    Nat Commun; 2022 Apr; 13(1):1984. PubMed ID: 35418171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salicylate in Pepto-Bismol.
    Med Lett Drugs Ther; 1980 Jul; 22(15):63. PubMed ID: 7393125
    [No Abstract]   [Full Text] [Related]  

  • 24. Interaction of bismuth subsalicylate with fruit juices, ascorbic acid, and thiol-containing substrates to produce soluble bismuth products active against Clostridium difficile.
    Mahony DE; Woods A; Eelman MD; Burford N; Veldhuyzen van Zanten SJ
    Antimicrob Agents Chemother; 2005 Jan; 49(1):431-3. PubMed ID: 15616328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisecretory and antiinflammatory properties of bismuth subsalicylate.
    Ericsson CD; Tannenbaum C; Charles TT
    Rev Infect Dis; 1990; 12 Suppl 1():S16-20. PubMed ID: 2305173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum concentrations of salicylic acid following topically applied salicylate derivatives.
    Morra P; Bartle WR; Walker SE; Lee SN; Bowles SK; Reeves RA
    Ann Pharmacother; 1996 Sep; 30(9):935-40. PubMed ID: 8876850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics of the salicylates.
    Needs CJ; Brooks PM
    Clin Pharmacokinet; 1985; 10(2):164-77. PubMed ID: 3888490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of capsular polysaccharide and potentiation of aminoglycoside inhibition in gram-negative bacteria by bismuth subsalicylate.
    Domenico P; Landolphi DR; Cunha BA
    J Antimicrob Chemother; 1991 Dec; 28(6):801-10. PubMed ID: 1816178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transmucosal penetration of bismuth particles in the human stomach.
    Nwokolo CU; Lewin JF; Hudson M; Pounder RE
    Gastroenterology; 1992 Jan; 102(1):163-7. PubMed ID: 1727749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin.
    Greenblatt DJ; Abernethy DR; Boxenbaum HG; Matlis R; Ochs HR; Harmatz JS; Shader RI
    Arthritis Rheum; 1986 Aug; 29(8):971-80. PubMed ID: 3741521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy.
    Bingham AL; Brown RO; Dickerson RN
    Nutr Clin Pract; 2013 Dec; 28(6):766-9. PubMed ID: 24163322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Black granules on the skin after bismuth subsalicylate ingestion.
    Ruiz-Maldonado R; Contreras-Ruiz J; Sierra-Santoyo A; López-Corella E; Guevara-Flores A
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):489-90. PubMed ID: 9308569
    [No Abstract]   [Full Text] [Related]  

  • 33. In vitro antimicrobial activity of bismuth subsalicylate and other bismuth salts.
    Manhart MD
    Rev Infect Dis; 1990; 12 Suppl 1():S11-5. PubMed ID: 2406851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fatal salicylate toxicity from bismuth subsalicylate.
    Sainsbury SJ
    West J Med; 1991 Dec; 155(6):637-9. PubMed ID: 1812638
    [No Abstract]   [Full Text] [Related]  

  • 35. In vitro antibacterial activity of bismuth subsalicylate.
    Cornick NA; Silva M; Gorbach SL
    Rev Infect Dis; 1990; 12 Suppl 1():S9-10. PubMed ID: 2305178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies on the absorption and excretion of tripotassium dicitrato-bismuthate in man.
    Lee SP
    Res Commun Chem Pathol Pharmacol; 1981 Nov; 34(2):359-64. PubMed ID: 7335960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanosynthesis of the metallodrug bismuth subsalicylate from Bi2O3 and structure of bismuth salicylate without auxiliary organic ligands.
    André V; Hardeman A; Halasz I; Stein RS; Jackson GJ; Reid DG; Duer MJ; Curfs C; Duarte MT; Friščić T
    Angew Chem Int Ed Engl; 2011 Aug; 50(34):7858-61. PubMed ID: 21739550
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of bismuth subsalicylate in relieving symptoms of indigestion.
    Hailey FJ; Newsom JH
    Arch Intern Med; 1984 Feb; 144(2):269-72. PubMed ID: 6365007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics of salicylates: a re-assessment.
    Levy G
    Br J Clin Pharmacol; 1980 Oct; 10 Suppl 2(Suppl 2):285S-290S. PubMed ID: 7437270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic salicylate toxicity due to consumption of over-the-counter bismuth subsalicylate.
    Vernace MA; Bellucci AG; Wilkes BM
    Am J Med; 1994 Sep; 97(3):308-9. PubMed ID: 8092182
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.